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ABSTRACT
Purpose: Methotrexate (MTX) is the first choice
conventional disease-modifying antirheumatic drug
(DMARD) for rheumatoid arthritis. It is not universally
effective, however; although to date it is not possible to
predict with any accuracy which patients will respond to
treatment. The aim of this analysis was to examine
whether clinical and genetic variables could be used to
predict response to MTX.
Methods: Patients recruited to the Norfolk Arthritis
Register (NOAR), a primary care based inception cohort of
patients with inflammatory polyarthritis, were eligible for
this analysis if they were commenced on MTX as their
first DMARD within 3 months of their baseline visit and
had at least 2 years of follow-up data. Outcome on MTX
was defined as: (1) stopped for adverse events; (2)
stopped for inefficacy or second DMARD added; (3)
stopped for other reasons; or (4) remained on MTX
monotherapy. Multiple logistic regression was used to
establish which variables (including demographics, dis-
ease activity and Health Assessment Questionnaire score)
predicted stopping monotherapy for inefficacy or adverse
event (with those remaining on treatment taken as the
referent category). The area under the Receiver Operating
Characteristic curves (AUC ROC), were used to determine
how accurate the model was at predicting outcome.
Results: 309 patients were included in this analysis. At
1 year (2 years), 34 (46) patients had stopped for
adverse events and 25 (49) had either stopped
monotherapy for inefficacy or had a second DMARD
added. 231 (188) patients remained on MTX mono-
therapy. The strongest predictor of inefficacy at both time
points was shared epitope positivity: odds ratios (OR) 5.8
(95% confidence intervals (CI) 1.3 to 25.6) at 1 year, OR
3.0 (95% CI 1.3 to 7.3) at 2 years. High Health
Assessment Questionnaire score (OR 1.84 95% CI 1.12 to
3.01) and female gender (OR 2.2, 95% CI 0.92 to 5.28)
were associated with adverse events on MTX at 1 year.
However, even the most optimal combinations of the
factors analysed were only weakly predictive of treatment
outcome: AUC ROC for adverse events 0.68 (95% CI 0.58
to 0.78) and for inefficacy AUC ROC 0.71 (95% CI 0.6 to
0.81).
Conclusions: Within this cohort, routine clinical and
laboratory factors were poor at predicting outcome of
treatment with MTX. Given the major therapeutic
advantage to be derived from accurate prediction of
treatment outcome, further studies will need to
investigate novel biological and other markers.
Methotrexate (MTX) is the key conventional
disease-modifying antirheumatic drug (DMARD)
treatment for rheumatoid arthritis (RA) as it is
cheap, effective and can be prescribed as mono-
therapy or in combination with other agents,
including biologicals. Studies suggest it is now
the first DMARD of choice for RA worldwide.
1
Recent studies have done much to confirm its
clinical efficacy with ACR50 responses between
46% and 65%.
23In addition, patients remain on
MTX significantly longer than other conventional
DMARDs.
45
MTX is, however, not universally effective, and
a significant proportion of patients stop treatment
because of inefficacy or adverse events. There are,
however, few data as to the possibility of being
able to predict patients’ response to treatment. As
patients usually have to fail treatment with MTX
prior to the prescription of biologicals it would be
particularly useful to be able to predict treatment
outcome, in that patients unlikely to respond to
treatment could be fast-tracked to drugs from
which they would be more likely to derive benefit.
Although outcome studies have identified RA-
related factors (eg, high erythrocyte sedimentation
rate/C-reactive protein (CRP), rheumatoid factor,
shared epitope (SE) positivity and extra-articular
disease)tobeassociatedwithanadverseprognosisin
RA in terms of radiographic damage or disability,
6 to
date few studies have examined the effect of such
factors on treatment outcome. Anderson et al
7
identified disease duration as the strongest predictor
of treatment response in a meta-analysis of 1435
patients, with patients with longer disease duration
at the start of treatment being less likely to respond
to MTX. Other factors suggested to be associated
with poorer response include previous DMARD
use
78 and poor functional status.
7 Clearly these
factors may be, in part, confounded by disease
duration, in that patients with a longer duration of
disease will usually have been exposed to more drugs
and have had longer to accrue physical disability.
Similarly, failure with other DMARDs might
indicate drug-resistant disease, or disease less likely
to respond to treatment.
Studies examining disease activity as a predictor
of MTX response are inconsistent, with some
studies suggesting that patients with low disease
activity are less likely to respond to treatment.
78
However, in a study published by Hoekstra et al,
9
patients with low disease activity at baseline were
more likely to respond to treatment with MTX. In
part, these differences may reflect the different
definitions of disease activity used, in that some
studies used inflammatory markers as a marker of
disease activity,
8 whereas others used composite
measures such as the disease activity score.
9
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determine whether clinical variables influence MTX response it
is necessary to study patients early in their disease course. The
Norfolk Arthritis Register (NOAR) provides an ideal population
for further study as patients are recruited at the time of
diagnosis, when data are recorded on disease activity and
severity and patients are followed annually. The aim of this
analysis was to examine whether clinical factors could be used
to predict outcome of treatment with MTX used as the first
DMARD in patients with early inflammatory polyarthritis (IP).
PATIENTS AND METHODS
Subjects
Subjects were recruited from NOAR, which is a primary care
based inception cohort of patients with early IP. Details of the
register have been published elsewhere.
10 Briefly, NOAR aims to
recruit all new cases of IP from a large defined geographical area
of approximately 400 000 adults (age >16 years). Any indivi-
dual presenting to their primary care physician with swelling of
two or more joints lasting at least 4 weeks should be notified to
NOAR. A parallel notification system operates from hospitals
within the catchment area. All patients who are referred to
secondary care are treated by one of four rheumatologists
according to their routine clinical practices. For the purposes of
this analysis all patients recruited to NOAR between 1 January
1995 and 31 December 2003 who were commenced on MTX as
their first DMARD within 3 months of their baseline visit were
eligible for inclusion. Clinical guidelines exist for the manage-
ment of patients on MTX, patients are started on a standard
dose MTX (7.5–10 mg/week) and monitored in accordance with
UK national guidelines, with dose escalation (up to 25 mg/
week) at the discretion of the treating rheumatologist. The
study was approved by the local research ethics committee and
all patients provided written consent. Patients were included in
this analysis if they were treated with MTX as their first
DMARD within 3 months of their baseline assessment and had
2 years of follow-up data.
Baseline assessment
One of a team of trained research nurses performed a structured
interview and clinical examination at the baseline and follow-up
assessments. Clinical and demographic data recorded included
age at symptom onset, gender, symptom duration, tender joint
count (TJC, 53 joints) and swollen joint count (SJC, 51 joints).
All patients also completed a Health Assessment Questionnaire
(HAQ), modified for use in British patients.
11 At baseline, blood
samples were taken for rheumatoid factor (RF) and C-reactive
protein (CRP) measurement and DNA was extracted for SE
status. RF was measured using a latex agglutination technique
and a titre of >1:40 was considered positive. SE status was
examined using the Dynal RELI SSO HLA-DRB1 Typing kit
(Dynal, Bromborough, UK). The disease activity score (using 28
joint counts) (DAS28) was calculated for each patient using the
28 SJC, 28 TJC and CRP using the formula
(DAS28=(0.566SQRT(TJC28)+0.286SQRT(SJC28)+0.366ln(-
CRP+1))61.10+1.15) (from Flendrie and Fransen http://www.
umcn.nl/userfiles/other/dasculators.xls/ accessed 23 September
2008).
Follow-up
Patients were then followed up annually using a nurse-
administered questionnaire and HAQ. This records medication
details, including start and stop date of DMARDs and reason for
stopping treatment. For this study the patient reported reason
for stopping treatment was validated by medical record and
laboratory data review. Outcome on MTX was then classified as
either: (1) stopped for an adverse event; (2) stopped for
inefficacy (physician statement) or had second DMARD added;
(3) stopped for other reasons; or (4) remained on treatment.
Statistical analysis
The baseline characteristics were compared between those who
stopped MTX treatment at 1 and at 2 years with those who
continued treatment at each time-point. Comparison of
continuous data was carried out using the Mann–Whitney U
test. For categorical data the x
2 test was employed. Logistic
regression models were used to assess the relationship between
predictor variables and the event of interest (either inefficacy or
adverse event) compared with remaining on MTX monotherapy
(which was taken as the referent category). An analysis that
examined predicting MTX failure (for either inefficacy or
adverse events) compared with remaining on MTX monother-
apy was also performed. The areas under the resulting Receiver
Operating Characteristic curve (AUC ROC, were used to
determine how accurate the models were at predicting outcome.
All analyses were performed using STATA 8.0 (STATA
Corporation, College Station, Texas, USA, 1993).
RESULTS
There were 309 patients who were eligible to be included in this
analysis. During the period of recruitment, 1707 patients were
ascertained by NOAR and the derivation of the 309 patients
included in this analysis is shown in fig 1. These were a typical
population with IP in that 66% were female, and median age at
symptom onset was 59.3 (interquartile range 48.3–69 years). As
expected there was a range of disease activity at baseline,
median DAS28 3.9 (interquartile range 3.0–4.8). At baseline 51%
of the cohort fulfilled American Rheumatism Association
criteria for RA,
12 which increased to 70% at 1 year. Figure 2
shows the outcome of MTX monotherapy at 1 and 2 years,
illustrating that treatment survival was good with 75% and 61%
of patients remaining on monotherapy at 1 and 2 years
respectively. Perhaps not surprisingly, more patients stopped
monotherapy because of adverse events in the first year and
because of inefficacy in the second. There was a small group of
patients who stopped for other reasons (including planning
pregnancy and patient choice). This latter group was excluded
from further analyses.
Predicting inefficacy
Cumulatively, 25 patients stopped MTX monotherapy for
inefficacy in the first year, and 49 patients had stopped
monotherapy at 2 years. Of these 49 patients, 35 had a second
DMARD added. Baseline clinical and demographic variables of
those stopping MTX monotherapy for inefficacy were similar to
those remaining on treatment (table 1).
By contrast, possession of the SE was associated with MTX
inefficacy at both 1 year (unadjusted OR 5.83 95% CI 1.33 to
25.6, p=0.02) and 2 years (unadjusted OR 3.04 95% CI 1.27 to
7.27, p=0.01). Adjusting for age, gender, symptom duration
and steroid use did not attenuate this association (table 2).
However, using the ROC curve, SE positivity was only
moderate in predicting MTX inefficacy at 12 months, AUC
ROC 0.64 (95% CI 0.48 to 0.75). By including all other variables
that showed some evidence of possible association (table 2) as
well as age, gender, symptom duration and steroid use did not
Extended report
58 Ann Rheum Dis 2009;68:57–62. doi:10.1136/ard.2008.088237significantly improve the predictive power of the model, AUC
ROC 0.7 (95% CI 0.6 to 0.81). The results were similar at 2 years
unadjusted AUC ROC 0.6 (95% CI 0.54 to 0.67) and adjusted for
the same variables AUC ROC 0.74 (95% CI 0.65 to 0.81).
Predicting adverse events
Thirty-four patients stopped MTX for adverse events in the first
year, this increased to 46 patients by 2 years. Baseline clinical
and demographics of the adverse event group compared with
those remaining on treatment are shown in table 3.
At 1 year, patients stopping MTX for adverse events had a
higher baseline median HAQ score (1.625 vs 1, p=0.02), higher
TJC (9 vs 5, p=0.05) but lower CRP (8 vs 13, p=0.04) than
those remaining on treatment. There was also a trend for female
patients to be more likely to stop MTX for adverse events (79%
vs 64%, p=0.07), although this did not reach statistical
significance. By 2 years, only lower CRP (7 vs 13, p=0.01)
was associated with stopping MTX for adverse events, although
a trend towards a higher TJC in those stopping for adverse
events remained. No association was observed between SE
status and adverse events on MTX. Using logistic regression,
higher baseline HAQ score was associated with stopping MTX
for adverse events at 1 year (unadjusted OR 1.84 95% CI 1.12 to
3.01, p=0.02). Adjusting for age, gender, symptom duration
and steroid use did not affect this association (table 4).
Despite this association, however, HAQ was only moderate
in predicting adverse events on MTX, AUC ROC unadjusted
0.63 (95% CI 0.52 to 0.73) and 0.68 (95% CI 0.58 to 0.78) when
adjusted for age, gender, symptom duration and steroid use.
Adding in the other factors significant on univariate analysis
(TJC and CRP) did not further improve the predictive power of
the model AUC ROC 0.69 (95% CI 0.6 to 0.79). At 2 years, the
results were similar, with a trend for higher HAQ to be
associated with stopping MTX for adverse events. This no
longer reached statistical significance (table 4).
Predicting methotrexate failure overall
Fifty-nine patients failed MTX monotherapy at 1 year, this
increased to 95 patients by 2 years. Baseline clinical and
demographics of the failure group compared with those
remaining on MTX monotherapy are shown in table 5. At
1 year, patients failing MTX monotherapy had a higher baseline
median HAQ score (1.5 vs 1, p=0.04) and were more likely to
be SE positive (78% vs 64%, p=0.05) than those remaining on
monotherapy, although neither of these associations remained
statistically significant at 2 years. Again these factors were poor
at predicting MTX failure, AUC ROC HAQ unadjusted 0.59
(95%CI 0.5 to 0.68) and 0.63 (95%CI 0.55 to 0.72) when adjusted
for age, gender, symptom duration and steroid use (table 6).
DISCUSSION
This cohort provides an insight into the ‘‘real world’’ response
to MTX within an unselected inception cohort of patients with
IP starting MTX as their first DMARD. Although the total
numbers starting MTX as their first DMARD (with clinical data
Table 2 Predicting inefficacy
Predictor
1 year 2 years
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
SE positive 5.83
(1.33 to 25.61)
0.02 5.88
(1.32 to 26.25)
0.02 3.04
(1.27 to 7.27)
0.01 3.04
(1.21 to 7.62)
0.02
MTX, methotrexate; SE, shared epitope.
This table illustrates the odds of stopping MTX for inefficacy—OR (95% CI) displayed as unadjusted and adjusted for age, gender,
symptom duration and steroid use at baseline.
Table 1 Predicting inefficacy at 1 and 2 years
Predictor
1 year 2 years
Inefficacy Still on p Value Inefficacy Still on p Value
Number of patients N (%) 25 (8) 231 (75) 49 (16) 188 (61)
Female gender N (%) 18 (72) 147 (64) 0.8 33 (67) 117 (62) 0.5
Age diagnosis (years) 60.6 (53.3–73.1) 59.3 (48.3–69) 0.34 60.6 (52.5–68.6) 58.7 (46.9–69.5) 0.43
Age MTX onset (years) 61.2 (53.9–73.2) 60 (50.8–69.8) 0.38 61.2 (53.1–68.7) 59.4 (49.1–70.5) 0.55
Symptom duration—prior MTX
(months)
6.01 (3.35–8.01) 6.27 (3.75–12.68) 0.38 6.01 (3.35–7.95) 6.09 (3.56–14.59) 0.11
RF positive (yes/no) 14 (56) 94 (41) 0.12 25 (51) 87 (46) 0.25
ARA criteria (yes/no) 11 (44) 121 (52) 0.43 25 (51) 101 (54) 0.74
SJC 7 (2–10) 4 (1–11) 0.8 5 (2–12) 5 (1–11) 0.72
TJC 4 (1–12) 5 (1–15) 0.94 4 (0–17) 5 (1–13) 0.77
28 SJC 4 (1–9) 4 (1–9) 0.84 4 (1–10) 4 (1–9) 0.64
28 TJC 3 (0–7) 3 (0–10) 0.28 3 (0–7) 4 (0–10) 0.26
Baseline CRP* 20 (6–36) 13 (5–26) 0.33 20 (6–38) 13 (5–26) 0.26
Baseline DAS28* 3.7 (2.8–4.7) 3.9 (3.0–4.8) 0.59 3.7 (2.8–4.8) 4.0 (3.0–4.8) 0.67
Baseline HAQ 1 (0.375–2) 1 (0.5–1.625) 0.57 1.125 (0.5–1.875) 1 (0.5–1.625) 0.34
SE positive (yes/no){ N (%) 21 (91) 126 (64) 0.009 37 (84) 99 (63) 0.01
Steroids (yes/no) 6 (24) 39 (17) 0.38 19 (38) 18 (10) 0.001
ARA, American Rheumatism Association; CRP, C-reactive protein; DAS, disease activity score (using 28 joint counts); HAQ, Health Assessment Questionnaire; MTX, methotrexate;
RF, rheumatoid factor; SE, shared epitope; SJC, swollen joint count; TJC, tender joint count.
This table illustrates clinical variables in those stopping for inefficacy and those remaining on treatment at 1 and 2 years. Results expressed as median (IQR) unless stated.
*293 patients had baseline CRP available and, therefore, could have DAS28 results calculated.
{260 patients had DNA samples and were successfully genotyped for SE.
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provides additional evidence that MTX is effective and generally
well tolerated in an unselected IP cohort, with 75% of patients
remaining on monotherapy at 1 year and 61% at 2 years.
Within this cohort, standard clinical and laboratory variables
collected at first visit were poorly predictive of treatment
outcome. Interestingly, the most strongly associated predictor
of MTX inefficacy at both 1 and 2 years was possession of the
SE, whereas other variables, such as CRP, DAS28 and HAQ, did
not appear to be associated with inefficacy. The majority of
patients stopping for adverse events did so within the first
12 months, within this group higher HAQ score, higher TJC
and lower CRP were associated with stopping treatment for
adverse events. However, for neither outcome were these
variables, even when used in combination, sufficiently pre-
dictive of outcome to be of clinical use.
Studies suggest that high levels of inflammation (as measured
by erythrocyte sedimentation rate, CRP or joint counts) predict a
poor prognosis in terms of radiological damage.
13 Our results
suggest that disease activitydoesnot influence treatment response
in either direction. It could be hypothesised that the patients with
the least active disease will do better because of their better
underlying natural history or conversely those who have the most
active disease have the greatest potential for showing a response.
Increased disability, as measured by the HAQ score, was
predictive for stopping treatment for adverse events, although
not for inefficacy. The explanation for this finding is unclear. In
other studies,
7 higher levels of disability (as measured by the
Steinbrocker functional class) were associated with a poorer
response to treatment, which may be explained on the basis
that chronic severe disease is less responsive to treatment, The
association in the current study seen with adverse events may
be explained by a high HAQ score being a marker for other
psychosocial factors that may increase adverse events such as
depression or altered illness beliefs. Previous studies have shown
that the HAQ score, although accepted as one of the gold
standard measures of disability in RA, is also associated with
pain,
14 depression and disease activity.
15
In a meta-analysis, Anderson et al
7 found that female patients
had a poorer response to treatment. Although within the NOAR
cohort, female patients were more likely to stop treatment for
adverse events, the difference was not statistically significant.
Other studies
9 suggest that male patients are more likely to
respond to MTX, although whether this relates to gender
differences in MTX clearance or other factors remains unclear.
Interestingly, the strongest factor demonstrated was the
association between being positive for the HLA DRB1 SE and
stopping MTX for inefficacy. Small numbers limited the ability
to be able to detect a dose effect, or the relative importance of
different SE alleles. No association was observed between
stopping MTX for adverse events and SE status. Other studies
support a link between SE and MTX efficacy; O’Dell et al
16
found that patients who were SE positive were less likely to
respond to MTX monotherapy compared with combination
Table 3 Predicting adverse events at 1 and 2 years
Predictor
1 year 2 years
Adverse event Still on p Value Adverse event Still on p Value
Number of patients 34 (11) 231 (75) 46 (15) 188 (61)
Female gender n (%) 27 (79) 147 (64) 0.07 35 (76) 117 (62) 0.08
Age diagnosis (years) 58.4 (44.5–64.4) 59.3 (48.3–69) 0.25 59 (45.1–65.6) 58.7 (46.9–69.5) 0.56
Age MTX onset (years) 58.8 (45.6–64.7) 60 (50.8–69.8) 0.29 59 (45.8–68.0) 59.4 (49.1–70.5) 0.6
Symptom duration prior to MTX
(months)
8.76 (4–18.95) 6.27 (3.75–12.68) 0.21 6.97 (4.01–16.79) 6.09 (3.56–14.59) 0.33
RF positive (yes/no) 11 (32) 94 (41) 0.31 15 (44) 87 (46) 0.2
ARA criteria (yes/no) 16 (47) 121 (52) 0.56 20 (44) 101 (54) 0.2
SJC 4 (2–10) 4 (1–11) 0.83 4 (2–9) 5 (1–11) 0.43
TJC 9 (2–15) 5 (1–15) 0.06 8 (3–16) 5 (1–13) 0.08
28 SJC 3 (2–8) 4 (1–9) 0.99 3 (1–7) 4 (1–9) 0.4
28 TJC 6 (3–9) 3 (0–10) 0.05 6 (2–11) 4 (0–10) 0.09
Baseline CRP* 8 (2–17) 13 (5–26) 0.04 7 (2–17) 13 (5–26) 0.01
Baseline DAS28* 3.8 (3.3–5.1) 3.9 (3.0–4.8) 0.65 3.6 (3.3–4.9) 4.0 (3.0–4.8) 0.86
Baseline HAQ 1.625 (0.875–2) 1 (0.5–1.625) 0.02 1.25 (0.875–2) 1 (0.5–1.625) 0.1
SE positive (yes/no){ 19 (68) 126 (64) 0.71 25 (63) 99 (63) 0.91
Steroids (yes/no) 5 (15) 39 (17) 0.75 9 (20) 18 (10) 0.06
ARA, American Rheumatism Association; CRP, C-reactive protein; DAS, disease activity score (using 28 joint counts); HAQ, Health Assessment Questionnaire; MTX, methotrexate;
RF, rheumatoid factor; SE, shared epitope; SJC, swollen joint count; TJC, tender joint count.
This table illustrates clinical variables in those stopping for adverse events and those remaining on treatment at 1 and 2 years. Results are expressed as median (IQR) unless stated.
*293 patients had baseline CRP available and, therefore, could have DAS28 results calculated.
{260 patients had DNA samples and were successfully genotyped for SE.
Table 4 Predicting adverse events
Predictor
1 year 2 years
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
HAQ score 1.84
(1.12 to 3.01)
0.02 1.87
(1.11 to 3.15)
0.02 1.47
(0.94 to 2.29)
0.09 1.42
(0.89 to 2.26)
0.14
HAQ, Health Assessment Questionnaire.
This table illustrates OR of stopping methotrexate for adverse events—OR displayed as unadjusted and adjusted for age, gender,
symptom duration and steroid use at baseline.
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whereas patients who were SE negative did equally well
regardless of treatment allocation. Our results are in contrast
to those of Criswell et al
17 who found that patients who were SE
positive were more likely to respond to MTX. Further studies are
required to reconcile these apparently contradictory results.
The strength of this study is that we were able to recruit an
unselected cohort of patients with IP and so the results are
generalisable to other unselected inflammatory arthritis cohorts.
The treatment of early IP is difficult because most of the
evidence base relates to patients who satisfy the American
College of Rheumatology (ACR) criteria. Yet it is increasingly
recognised that treatment should be started as early as possible
before the ACR criteria have been satisfied, with the PROMPT
(Probable rheumatoid arthritis: Methotrexate versus Placebo
Treatment) study showing benefit of early introduction of
MTX in patients with undifferentiated IP in terms of slowing
the progression to ‘‘ACR criteria’’ RA.
18 Thus it is a strength of
this study that it adds to the evidence base of the efficacy of
treatment in patients with undifferentiated IP. There are,
however, a number of limitations. First, the measure of disease
response was not based on a formal protocol but reflected
physician opinion. Hence the decision to stop treatment
because of inefficacy was not standardised between patients.
Further, as the NOAR follow-up was based on anniversary since
entry, we do not have the detailed clinical data on disease
activity and drug dose; for example, at the time of stopping
treatment to obtain objective data to support the decision to
stop treatment. This also meant that a number of patients were
excluded from the analysis either because they had already
started on MTX, or did not start within 3 months of their
clinical assessment. Furthermore, there are additional, unmea-
sured predictors that may influence treatment response in this
cohort, and hence improve the fit of the prediction models. We
did not have radiographic data available on all patients and so
these could not be included in the analysis. As this was a
primary care based cohort of early disease, with short symptom
duration, it was assumed that the prevalence of erosive disease
at baseline would be low and, therefore, x-rays were not
routinely taken on all patients at baseline.
Despite its limitations, this study highlights that clinical and
laboratory factors per se, even in combination, are relatively
poor at predicting treatment response to MTX at least as judged
by physician decision to stop treatment. This suggests that,
first, there is no simple decision rule that could guide which
patients should and should not be commenced on MTX.
Secondly, given that response to treatment is unlikely to be a
truly random event, there must be a number of other
biomarkers, for example, not measured in this study that may
influence outcome of MTX treatment. There have been several
studies suggesting that polymorphisms in some of the pathways
involved in the metabolism of MTX may be useful in predicting
drug outcome,
19 with a recent pharmacogenetic model being
used to predict drug outcome in a subset of patients.
20 To date,
the clinical utility of such a model has still to be fully
established. Further attempts to refine our ability to predict
treatment response may therefore need to incorporate both
additional genetic biomarkers and psychosocial factors, such as
Table 5 Predicting MTX failure
Predictor
1 year 2 years
MTX fail Still on p Value MTX fail Still on p Value
Number of patients 59 (25) 231 (75) 95 188 (61)
Female gender n (%) 45 (76) 147 (64) 0.07 68 (72) 117 (62) 0.1
Age diagnosis (years) 58.9 (45.4–70.5) 59.3 (48.3–69) 0.8 59.3 (52–68.2) 58.7 (46.9–69.5) 0.88
Age MTX onset (years) 58.9 (47.8–71) 60 (50.8–69.8) 0.82 59.9 (52.2–68.8) 59.4 (49.1–70.5) 0.95
Symptom duration prior to MTX
(months)
6.24 (3.6–13.18) 6.27 (3.75–12.68) 0.72 6.28 (3.64–13.04) 6.09 (3.56–14.59) 0.66
RF positive (yes/no) 25 (45) 94 (41) 0.84 40 (44) 87 (46) 0.95
ARA criteria (yes/no) 27 (46) 121 (52) 0.36 45 (47) 101 (54) 0.3
SJC 5 (2–10) 4 (1–11) 0.76 5 (2–10) 5 (1–11) 0.79
TJC 8 (2–15) 5 (1–15) 0.19 6 (1–16) 5 (1–13) 0.35
28 SJC 3 (2–8) 4 (1–9) 0.89 3 (1–8) 4 (1–9) 0.83
28 TJC 5 (1–9) 3 (0–10) 0.46 4 (0–9) 4 (0–10) 0.73
Baseline CRP* 10 (2–26) 13 (5–26) 0.38 10 (3–28) 13 (5–26) 0.86
Baseline DAS28* 3.71 (3.1–4.9) 3.9 (3.0–4.8) 0.99 3.7 (3.1–4.9) 4.0 (3.0–4.8) 0.69
Baseline HAQ 1.5 (0.625–2) 1 (0.5–1.625) 0.04 1.25 (0.625–1.875) 1 (0.5–1.625) 0.1
SE positive (yes/no){ 40 (78) 126 (64) 0.05 62 (74) 99 (63) 0.1
Steroids (yes/no) 11 (18.6) 39 (16.9) 0.75 28 (29) 18 (10) 0.001
ARA, American Rheumatism Association; CRP, C-reactive protein; DAS, disease activity score (using 28 joint counts); HAQ, Health Assessment Questionnaire; MTX, methotrexate;
RF, rheumatoid factor; SE, shared epitope; SJC, swollen joint count; TJC, tender joint count.
*293 patients had baseline CRP available and, therefore, could have DAS28 results calculated.
{260 patients had DNA samples and were successfully genotyped for SE.
Table 6 Predicting methotrexate failure
Predictor
1 year 2 years
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
HAQ score 1.55 (1.05 to 2.3) 0.03 1.47 (0.98 to 2.2) 0.06 1.35 (0.97 to 1.9) 0.08 1.34 (0.93 to 1.93) 0.1
SE positive 2.02 (0.98 to 4.18) 0.05 2.5 (1.2 to 5.47) 0.02 1.62 (0.9 to 2.9) 0.1 1.75 (0.94 to 3.27) 0.08
HAQ, Health Assessment Questionnaire; SE, shared epitope.
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Ann Rheum Dis 2009;68:57–62. doi:10.1136/ard.2008.088237 61compliance, patient education and illness beliefs, which may
influence treatment response.
In summary, routinely gathered clinical and laboratory
factors are poor at predicting outcome of treatment with
MTX in patients with newly diagnosed inflammatory arthritis.
Nevertheless, given the central importance of MTX in the
management of RA further work is required to optimise our use
of this treatment.
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